立复欣肝毒性临床观察

Observation of the liver toxicity of Rifamycin

目的 :观察立复欣的肝毒性。方法 :利用利福平作对照 ,通过对结核病患者的用药 ,每 2周复查肝功能 1次 ,连续观察 2个月 ,出现GPT、SB、SB1 3项中的 1项异常者即计为肝功能异常病例。结果 :利福平组肝功能异常 13例 ,其中GPT升高 13例 ,合并SB升高 2例。利福平组肝功能异常出现率为 13% ;立复欣组肝功能异常 4例 ,其中GPT升高 4例 ,无SB升高病例。立复欣组肝功能异常出现率为 4 % ,两组相比较有显著性差异。结论 :立复欣的肝毒性低于利福平 ,作为静脉用药剂型 ,临床使用是安全的。

Objective: To observe the liver toxicity caused by Rifamycin. Methods: Controls were treated by Rifampin. All cases were checked liver function every two weeks for two months. The abnormal of one of GPT , SB, SB 13 were liver function abnormal. Results: 13 cases liver function is abnormal in rifampin group, 13 cases showed abnormal GPT and 2 cases merged SB abnormal. The abnormal rate of rifampin group is 13%. 4 cases'liver function is abnormal in rifamycin group, 4 cases with abnormal GPT, no case with abnormal SB. The abnormal rate of rifamycin group is 4%. So the liver injury rate were significantly different. Conclusion: It showed that the liver toxicity of rifamycin was lower than rifampin. As an injection, rifamycin is safe in treating patients with tuberculosis.